|Over a week ago|
MorphoSys price target raised to EUR 110 from EUR 105 at Barclays » 11:4210/0210/02/20
Barclays analyst Emmanuel…
Barclays analyst Emmanuel Papadakis raised the firm's price target on MorphoSys to EUR 110 from EUR 105 and keeps an Equal Weight rating on the shares.
MorphoSys CFO Holstein to step down effective December 31, 2020 » 16:3109/3009/30/20
MorphoSys announced that…
MorphoSys announced that Jens Holstein, Chief Financial Officer, has decided to step down as CFO and member of the company's Management Board, effective December 31, 2020. Holstein will continue in his role through the end of the year to ensure an orderly transition. The company has commenced a search process to identify the future chief financial officer. "Jens Holstein has been truly instrumental in building MorphoSys to a fully integrated biopharma company, providing valuable medicines to patients suffering from serious diseases. Since joining in 2011, Jens' numerous contributions added substantially to making the company the success story that it is today. He leaves MorphoSys in a position, operationally and financially, which will allow us to continue providing much needed therapies in the years to come", said Marc Cluzel, M.D., Chairman of the Supervisory Board of MorphoSys. "I understand his wish for new challenges and on behalf of the entire Supervisory Board, I would like to thank him for his excellent contribution and wish him all the best for the future."
Incyte and MorphoSys to hold a joint conference call » 08:2509/2909/29/20
Incyte and MorphoSys hold…
Incyte and MorphoSys to hold a joint conference call » 04:5509/2909/29/20
Incyte and MorphoSys hold…
Incyte and MorphoSys to hold a joint conference call » 17:1709/2509/25/20
Incyte and MorphoSys hold…
|Over a month ago|
I-MAB, MorphoSys announce FDA clearance of IND for MOR210/TJ210 » 16:0709/1709/17/20
MorphoSys (MOR) and I-Mab…
MorphoSys (MOR) and I-Mab (IMAB) jointly announced that the U.S. FDA has cleared the Investigational New Drug application for MorphoSys' investigational human anti-C5aR1 antibody MOR210/TJ210 for the treatment of relapsed or refractory advanced solid tumors. The phase 1 clinical trial, designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of MOR210/TJ210, may proceed and is expected to commence subsequently. MorphoSys and I-Mab entered into an exclusive strategic collaboration and licensing agreement to develop and commercialize MOR210/TJ210 in November 2018. Under the terms of agreement, I-Mab receives exclusive rights to develop and commercialize MOR210/TJ210 in Greater China and South Korea, while MorphoSys retains rights in other parts of the world. With support from MorphoSys, I-Mab will also fund and conduct all global development activities of MOR210/TJ210, including clinical trials in China and the U.S., towards clinical proof-of-concept in oncology. The two companies are also collaborating on MorphoSys' investigational human CD38 antibody MOR202/TJ202. I-Mab owns the exclusive rights for development and commercialization in mainland China, Taiwan, Hong Kong and Macao and started two registrational trials to evaluate MOR202/TJ202 in patients with relapsed or refractory multiple myeloma in 2019.
Incyte, Morphosys announce Monjuvi included in NCCN guidelines » 16:0608/1808/18/20
MorphoSys AG (MOR) and…
MorphoSys AG (MOR) and Incyte (INCY) announced that Monjuvi, a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, has been included in the latest National Comprehensive Cancer Network Clinical Practice Guidelines, NCCN Guidelines, in Oncology for B-cell Lymphomas. Specifically, the NCCN Guidelines in the United States now include Monjuvi in combination with lenalidomide with a Category 2A designation as an option for the treatment of previously-treated adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, including DLBCL arising from low grade lymphoma who are ineligible for autologous stem cell transplant.
MorphoSys initiated with a Buy at Citi » 06:3908/1008/10/20
Citi analyst Vineet…
Citi analyst Vineet Agrawal initiated coverage of MorphoSys with a Buy rating and EUR 160 price target.
MorphoSys FDA approval in line with expectations, says Deutsche Bank » 13:2708/0308/03/20
Deutsche Bank analyst…
Deutsche Bank analyst Rajan Sharma reiterated a Buy rating and EUR129 price target on MorphoSys (MOR) after the company and Incyte (INCY) announced conditional FDA approval of Fc-engineered CD19 antibody tafasitamab in combination with Revlimid for the treatment of relapsed/refractory diffuse large B-cell lymphoma ahead of its August 30 PDUFA data. The analyst said that approval is in line with his expectations.
Monjuvi U.S. launch a solid long-term contributor for Incyte, says Piper Sandler » 11:1008/0308/03/20
Piper Sandler analyst…
Piper Sandler analyst Tyler Van Buren notes that Incyte (INCY) and partner MorphoSys (MOR) hosted a call on Monday to review the approval of Monjuvi. Based on management's comments, the analyst thinks the pricing is reasonable considering the observed treatment benefit, and continues to have confidence in the upcoming Monjuvi U.S. launch given the synergies that will likely be realized by leveraging Incyte's current Jakafi infrastructure and recent experience from the Pemazyre virtual drug launch. Recall that it is a 50/50 profit share in the U.S., so substantial profit likely won't be realized until next year, but still could be a meaningful $300M profit contributor long-term, he contends. Van Buren has an Overweight rating and a price target of $110 on Incyte's shares.